Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’) Ind-Swift Laboratories has informed that the Board of Directors of the Company in their meeting held today 7th November, 2023, have considered and approved the Standalone and Consolidated Un-audited Financial Results of the company for the quarter and half year ended 30th September, 2023. These Financial Results are subject to limited review. The Limited Review Report as submitted by the Statutory Auditors is also enclosed along with the Unaudited Financial Results. The un-audited financial results of the Company will also be available on the website of the Company: www.indswiftlabs.com. The Board Meeting commenced at 01:00 pm and concluded at 03:45 pm.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1751.05 |
Dr. Reddys Lab | 1163.70 |
Cipla | 1515.45 |
Lupin | 1936.75 |
Zydus Lifesciences | 831.40 |
View more.. |